Cochrane · systematic review · CD013532
Granulocyte colony‐stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease
Colli, A, Fraquelli, M, Prati, D, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
4
No studies
1
Included studies
NR
No studies 1 · 20%Ungraded 0 · 0%Very low 4 · 80%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Granulocyte colony‐stimulating factor (G‐CSF) with or without stem or progenitor cell infusion for people with compensated or decompensated advanced chronic liver disease
Population: adults with compensated or decompensated advanced chronic liver disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes  | no estimate extracted | NR | No studies |
All‐cause mortality at maximum | RR 0.53 [0.38, 0.72] | 20 studies · 1419 participants | Very low Downgraded: risk of bias, inconsistency |
Proportion of participants with 1 or more serious adverse events at maximum | RR 1.03 [0.66, 1.61] | 3 studies · 315 participants | Very low Downgraded: risk of bias, inconsistency |
Health‐related quality of life ‐ PCS physical component summary ‐ MCS mental component summary at maximum | no estimate extracted | 2 studies · 165 participants | Very low Downgraded: risk of bias, inconsistency |
Proportion of participants with liver disease‐related morbidity at maximum | RR 0.4 [0.17, 0.92] | 4 studies · 195 participants | Very low Downgraded: risk of bias, imprecision |